Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Who May Qualify: 1. Patients with diagnosis of first-line or second-line recurrent epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma, who has previously received at least 4 cycles of platinum-based chemotherapy in initial treatment; 2. Relapse occurred after 6 month since platinum-based chemotherapy; 3. PARPi maintenance therapy for more than 6 months before relapse; 4. R0 ideal debulking in initial surgery; 5. PET-CT indicate the recurrence lesion is isolated and not exceed 5 sites, and the ascites is less than 500ml; 6. ECOG/WHO Performance score of 0 to 1; 7. No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT and ALAT ≤ 3 time the Upper Normal Limit 8. No Renal insufficiency (serum creatinine \< 1,5 time the normal limit, creatinine clearance \> 80 mL/min). calculated with MDRD method 9. Hematology function: PNN ≥ 1,5x10⁹/L, platelet count at least 100x10⁹/L 10. No contraindication to general anaesthesia for heavy surgery 11. Patients having read, signed and dated willing to sign a consent form before any study procedure Who Should NOT Join This Trial: 1. Platinum-refractory/uncontrolled epithelial ovarian cancer; 2. Non-epithelial ovarian tumor, mucinous, serous-mucinous (mainly mucinous), malignant Brenner tumor, low-grade serous carcinoma, borderline tumor; 3. Suffering from other malignant tumors that have not achieved complete remission in the past 2 years; 4. Received radiotherapy within 2 weeks before the start of the study intervention; 5. General conditions cannot tolerate secondary cytoreduction; 6. Severe hypersensitivity reactions (≥ grade 3) to paclitaxel or platinum and/or any of its excipients. Always talk to your doctor about whether this trial is right for you.